ZEB1 and ZEB2 gene editing mediated by CRISPR/Cas9 in A549 cell line.
CRISPR/Cas9
ZEB1
ZEB2
gene editing
lung cancer A549.
Journal
Bratislavske lekarske listy
ISSN: 0006-9248
Titre abrégé: Bratisl Lek Listy
Pays: Slovakia
ID NLM: 0065324
Informations de publication
Date de publication:
2020
2020
Historique:
entrez:
18
1
2020
pubmed:
18
1
2020
medline:
6
2
2020
Statut:
ppublish
Résumé
One of the best approaches for recognition of protein function is the induction of mutations for a gene knockout. In line with this strategy, gene editing tools allow researchers to induce these mutations. Lung cancer is one of the leading causes of death worldwide. ZEB1 and ZEB2 genes are the candidates for this disease. The ZEB1 and ZEB2 knockout in the non-small cell lung cancer cell line (A549 cell) was investigated. Purification of recombination plasmids was performed from bacteria and then was transported to the A549 cell line. The deletion of ZEB1 and ZEB2 were examined by PCR. The results demonstrated the mutation and deletion in ZEB1 and ZEB2 genes. Based on the findings of this study, A549 cells were transfected with the vectors carrying the sgRNA/Cas9, simultaneously. The DNA fragment demonstrated the presence of indels in target sites as well as provided the potential of CRISPR/Cas9 system. CRISPR/Cas9 offers a great potential as an efficient technique for editing of ZEB1 and ZEB2 genes in A549 cell line (Tab. 1, Fig. 6, Ref. 44).
Identifiants
pubmed: 31950837
doi: 10.4149/BLL_2020_005
doi:
Substances chimiques
ZEB1 protein, human
0
ZEB2 protein, human
0
Zinc Finger E-box Binding Homeobox 2
0
Zinc Finger E-box-Binding Homeobox 1
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM